NEW ORLEANS, LA (June 21, 2004) – Changes in markers of bone remodeling after one month of treatment with Lilly’s Forteo may provide important early evidence of treatment response, according to new data presented last week at the 86th Annual Meeting of The Endocrine Society.
The test was conducted on 1,637 women with osteoporosis. Of the 527 patients in the Fracture Prevention Trial, several changes were noted, including changes in markers of bone remodeling.
Forteo was granted FDA approval on November 26, 2002. It stimulates new bone formation by increasing the number and activity of bone forming cells called osteoblasts.
Lilly is developing a portfolio of pharmaceutical products by applying research from its own laboratories and from collaborations with eminent scientific organizations.
